EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Efficacy of Mesalamine in Irritable Bowel Syndrome

Cong Dai, Min Jiang, Yu-Hong Huang

Clinical Gastroenterology and Hepatology · 2023

DOI: 10.1016/j.cgh.2023.03.021 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023. Verfasst von Cong Dai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China. Hauptthemen laut MEDLINE: Mesalamine, Irritable Bowel Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MesalamineIrritable Bowel SyndromeHumansAnti-Inflammatory Agents, Non-SteroidalDiarrhea

Substanzen

MesalamineAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China.

Zitieren

APA

Dai, C., Jiang, M., & Huang, Y. H. (2023). Efficacy of Mesalamine in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.03.021

Vancouver

Dai C, Jiang M, Huang YH. Efficacy of Mesalamine in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology. 2023. doi:10.1016/j.cgh.2023.03.021

BibTeX
@article{Dai2023,
  author = {Dai, Cong and Jiang, Min and Huang, Yu-Hong},
  title = {Efficacy of Mesalamine in Irritable Bowel Syndrome},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1016/j.cgh.2023.03.021}
}
Kostenlos starten →